Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Administration of LY-N001 Injection in Subjects With Moderate to Advanced Parkinson's Disease Carrying GBA1 Mutations

NCT07685444 is registered in ClinicalTrials.gov with Lingyi Biotech Co., Ltd. as lead sponsor.

NCT NCT07685444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07685444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm, Single-Dose Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebral Administration of LY-N001 Injection in Subjects With Moderate to Advanced Parkinson's Disease Carrying GBA1 Mutations
Lead sponsor
Lingyi Biotech Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
July 7, 2026
Completion date
December 30, 2032
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson's disease (pd)